Metabolic syndrome and cardiometabolic risk in PCOS

Current Diabetes Reports

Volumn 7, Issue 1, 2007, Pages 66-73

  Cussons, Andrea J ^a   Stuckey, Bronwyn G A ^a   Watts, Gerald F ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ANTIANDROGEN; CYPROTERONE ACETATE; ENDOTHELIN 1; ESTROGEN; FLUTAMIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; MALONALDEHYDE; METFORMIN; MINERALOCORTICOID ANTAGONIST; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRASTERONE SULFATE; RESISTIN; SPIRONOLACTONE; TROGLITAZONE; VON WILLEBRAND FACTOR;

ANOVULATION; ARTERY CALCIFICATION; ARTERY COMPLIANCE; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD CLOTTING DISORDER; CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORRELATION FUNCTION; DIABETES MELLITUS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCOSE TOLERANCE; HEART FUNCTION; HIGH RISK PATIENT; HUMAN; HYPERANDROGENISM; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESPAN; LIFESTYLE MODIFICATION; LUNG INSUFFICIENCY; MENSTRUAL IRREGULARITY; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PREGNANCY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SLEEP APNEA SYNDROME; THROMBOEMBOLISM; VASCULAR DISEASE; WEIGHT GAIN;

ANDROGENS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; METABOLIC SYNDROME X; POLYCYSTIC OVARY SYNDROME; RISK FACTORS;

EID: 33847388554     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-007-0012-8     Document Type: Review

References (51)

1. Alberti K, Zimmet P: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) [no authors listed]. JAMA 2001, 285:2486-2497.
3. Alberti KG, Zimmet P, Shaw J: Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23:469-480.
4. Dokras A, Bochner M, Hollinrake E, et al.: Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005, 106:131-137.
5. Faloia E, Canibus P, Gatti C, et al.: Body composition, fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome. J Endocrinol Invest 2004, 27:424-429.
6. Vrbikova J, Vondra K, Cibula D, et al.: Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum Reprod 2005, 20:3328-3332.
7. Vural B, Caliskan E, Turkoz E, et al.: Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 2005, 20:2409-2413.
8. Talbott EO, Zborowski JV, Rager JR, et al.: Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89:5454-5461.
9. Apridonidze T, Essah PA, Iuorno MJ, et al.: Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:1929-1935.
10. Azziz R: How prevalent is metabolic syndrome in women with polycystic ovary syndrome? Nat Clin Pract Endocrinol Metab 2006, 3:132-133.
11. Ehrmann DA, Liljenquist DR, Kasza K, et al.: Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91:48-53.
12. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18:774-800.
13. Talbott E, Guzick D, Clerici A, et al.: Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995, 15:821-826.
14. Norman RJ, Masters L, Milner CR, et al.: Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001, 16:1995-1998.
15. Barber TM, McCarthy MI, Wass JA, et al.: Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006, 65:137-145.
16. Legro RS: Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev 2003, 24:302-312.
17. Velazquez ME, Bellabarba GA, Mendoza S, et al.: Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin. Fertil Steril 2000, 74:1159-1163.
18. Okamoto Y, Kihara S, Funahashi T, et al.: Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006, 110:267-278.
19. Orio F Jr, Palomba S, Cascella T, et al.: Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003, 88:2619-2623.
20. Boulman N, Levy Y, Leiba R, et al.: Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004, 89:2160-2165.
21. Orio F Jr, Palomba S, Cascella T, et al.: The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:2-5.
22. Sampson M, Kong C, Patel A, et al.: Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1996, 45:623-629.
23. Dahlgren E, Janson PO, Johansson S, et al.: Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 1994, 61:455-460.
24. Diamanti-Kandarakis E, Spina G, Kouli C, et al.: Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001, 86:4666-4673.
25. Sabuncu T, Vural H, Harma M, et al.: Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 2001, 34:407-413.
26. Orio F Jr, Giallauria F, Palomba S, et al.: Cardiopulmonary impairment in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006, 91:2967-2971.
27. Vgontzas AN, Legro RS, Bixler EO, et al.: Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001, 86:517-520.
28. Kelly CJ, Speirs A, Gould GW, et al.: Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:742-746.
29. Cussons AJ, Stuckey BG, Watts GF: Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006, 185:227-239.
30. Orio FJ, Palomba S, Spinelli L, et al.: The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004, 89:3694-3695.
31. Burghen GA, Givens JR, Kitabchi AE: Correlation of hyper-androgenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980, 50:113-116.
32. Wu FC, von Eckardstein A: Androgens and coronary artery disease. Endocr Rev 2003, 24:183-217.
33. Dahlgren E, Janson PO, Johansson S, et al.: Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women Acta Obstet Gynecol Scand 1992, 71:599-604.
34. Wild S, Pierpoint T, McKeigue P, et al.: Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000, 52:595-600.
35. Solomon CG, Hu FB, Dunaif A, et al.: Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002, 87:2013-2017.
36. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al.: Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000, 20:2414-2421.
37. Orio F Jr, Palomba S, Cascella T, et al.: Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89:4588-4593.
38. Meyer C, McGrath BP, Cameron J, et al.: Vascular dysfunction and metabolic parameters in polycystic ovary syndrome. J Clin Endocrinol Metab 2005, 90:4630-4635.
39. Grundy SM: Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 2006, 5:295-309.
40. Huber-Buchholz MM, Carey DG, Norman RJ: Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999, 84:1470-1474.
41. Knowler WC, Barrett-Connor E, Fowler SE, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
42. Glueck CJ, Papanna R, Wang P, et al.: Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. Metabolism 2003, 52:908-915.
43. Orio F Jr, Palomba S, Cascella T, et al.: Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005, 90:6072-6076.
44. Topcu S, Tok D, Caliskan M, et al.: Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. Clin Endocrinol (Oxf) 2006, 65:75-80.
45. Brettenthaler N, De Geyter C, Huber PR, et al.: Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004, 89:3835-3840.
46. Paradisi G, Steinberg HO, Shepard MK, et al.: Troglitazone therapy improves endothelial function to near normal levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003, 88:576-580.
47. Xiang AH, Peters RK, Kjos SL, et al.: Effect of pioglitazone on pancreatic beta-call function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006, 55:517-522.
48. Graff-Iversen S, Hammar N, Thelle DS, et al.: Use of oral contraceptives and mortality during 14 years' follow-up of Norwegian women. Scand J Public Health 2006, 34:11-16.
49. Diamanti-Kandarakis E, Baillageon JP, Iuorno MJ, et al.: A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. J Clin Endocrinol Metab 2003, 88:1927-1932.
50. Macdonald JE, Kennedy N, Struthers AD: Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 2004, 90:765-770.
51. Daviglus ML, Stamler J, Pirzada A, et al.: Favorable cardiovascular risk profile in young women and long-term risk of cardiovascular and all-cause mortality. JAMA 2004, 292:1588-1592.